BRIEF-Arcutis Canada Says Health Canada Approves ZORYVE Foam 0.3% For Scalp, Body Psoriasis For Adults & Adolescents 12 & Older

Reuters11-13

Nov 13 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O:

ARCUTIS CANADA: HEALTH CANADA APPROVES ZORYVE FOAM 0.3% FOR SCALP, BODY PSORIASIS FOR ADULTS & ADOLESCENTS AGES 12 & OLDER CANADA NEWSWIRE

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583598728?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 21:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583598728","market":"fut","top_or_hot":-1,"title":"BRIEF-Arcutis Canada Says Health Canada Approves ZORYVE Foam 0.3% For Scalp, Body Psoriasis For Adults & Adolescents 12 & Older","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Arcutis Canada Says Health Canada Approves ZORYVE Foam 0.3% For Scalp, Body Psoriasis For Adults &amp; Adolescents 12 &amp; Older</title></head><body><p><span>Nov 13 (Reuters)</span><span> - </span><span><a href=\"https://laohu8.com/S/ARQT\">Arcutis Biotherapeutics</a> Inc <span>ARQT.O</span>:</span></p><ul><li><p>ARCUTIS CANADA: HEALTH CANADA APPROVES ZORYVE FOAM 0.3% FOR SCALP, BODY PSORIASIS FOR ADULTS &amp; ADOLESCENTS AGES 12 &amp; OLDER CANADA NEWSWIRE</p></li></ul><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Arcutis Canada Says Health Canada Approves ZORYVE Foam 0.3% For Scalp, Body Psoriasis For Adults & Adolescents 12 & Older</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Arcutis Canada Says Health Canada Approves ZORYVE Foam 0.3% For Scalp, Body Psoriasis For Adults & Adolescents 12 & Older\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 21:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Arcutis Canada Says Health Canada Approves ZORYVE Foam 0.3% For Scalp, Body Psoriasis For Adults &amp; Adolescents 12 &amp; Older</title></head><body><p><span>Nov 13 (Reuters)</span><span> - </span><span><a href=\"https://laohu8.com/S/ARQT\">Arcutis Biotherapeutics</a> Inc <span>ARQT.O</span>:</span></p><ul><li><p>ARCUTIS CANADA: HEALTH CANADA APPROVES ZORYVE FOAM 0.3% FOR SCALP, BODY PSORIASIS FOR ADULTS &amp; ADOLESCENTS AGES 12 &amp; OLDER CANADA NEWSWIRE</p></li></ul><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARQT","symbol_name":"Arcutis Biotherapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP0M6:1","article_id":"2583598728","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583598728","pubTimestamp":1763040153,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Arcutis Canada Says Health Canada Approves ZORYVE Foam 0.3% For Scalp, Body Psoriasis For Adults & Adolescents 12 & OlderNov 13  - Arcutis Biotherapeutics Inc ARQT.O:ARCUTIS CANADA: HEALTH CANADA APPROVES ZORYVE FOAM 0.3% FOR SCALP, BODY PSORIASIS FOR ADULTS & ADOLESCENTS AGES 12 & OLDER CANADA NEWSWIRE ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARQT":"Arcutis Biotherapeutics Inc.","BK4139":"生物科技"},"translate_title":"简介-Arcutis Canada表示加拿大卫生部批准ZORYVE Foam 0.3%用于治疗成人和12岁及以上青少年的头皮、身体银屑病","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":0.9},"content_text":"BRIEF-Arcutis Canada Says Health Canada Approves ZORYVE Foam 0.3% For Scalp, Body Psoriasis For Adults & Adolescents 12 & OlderNov 13 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O:ARCUTIS CANADA: HEALTH CANADA APPROVES ZORYVE FOAM 0.3% FOR SCALP, BODY PSORIASIS FOR ADULTS & ADOLESCENTS AGES 12 & OLDER CANADA NEWSWIRE ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583598728","isCrawlerRequest":true}